Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Shares Outstanding (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Shares Outstanding data on record, last reported at $36.0 million in Q3 2025.

  • For Q3 2025, Shares Outstanding rose 38.57% year-over-year to $36.0 million; the TTM value through Sep 2025 reached $36.0 million, up 38.57%, while the annual FY2024 figure was $27.1 million, 67.42% up from the prior year.
  • Shares Outstanding reached $36.0 million in Q3 2025 per GANX's latest filing, up from $30.8 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $36.0 million in Q3 2025 and bottomed at $11.9 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $17.9 million, with a median of $12.6 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: soared 901.77% in 2021, then changed 0.0% in 2022.
  • A 5-year view of Shares Outstanding shows it stood at $11.9 million in 2021, then changed by 0.0% to $11.9 million in 2022, then soared by 36.38% to $16.2 million in 2023, then surged by 67.42% to $27.1 million in 2024, then surged by 32.59% to $36.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $36.0 million in Q3 2025, $30.8 million in Q2 2025, and $28.7 million in Q1 2025.